Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8405699 | 0.83 | GAA (0.48) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL3539564 | 0.82 | KDM4E (0.36) | KDM4EMEN1GRIN2DGRIN3BALDH1A1 | |
| SCHEMBL5350262 | 0.71 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL9033475 | 0.71 | — | — | |
| SCHEMBL7402869 | 0.71 | HSD17B10 (0.41) | ALDH1A1CYP1A2HPGDTSHRSMN1; SMN2 | |
| SCHEMBL7631911 | 0.71 | MAPK13 (0.32) | MAPK13CDK1PIM1DYRK1APIM3 | |
| SCHEMBL1115538 | 0.67 | GAA (0.48) | KDM4EMEN1ALDH1A1LMNAMAPT | |
| SCHEMBL6021382 | 0.66 | TSHR (0.53) | MEN1GRIN2DGRIN3BALDH1A1LMNA | |
| SCHEMBL7784289 | 0.65 | GRIN2D (0.43) | KDM4EMEN1GRIN2DGRIN3BALDH1A1 | |
| SCHEMBL1413188 | 0.65 | AHR (0.45) | KDM4EMEN1GRIN2DGRIN3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3068519-A | — | — | None | — | — | JP | disclosed |
| US-20250161238-A1 | NMDAR Antagonists Prevent Ageing and Aging-Associated Conditions and Diseases Through Increasing 20S Proteasome Activity | SAHIN FIKRET (TR) | 2025-05-22 | — | — | US | disclosed |
| EP-4475953-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN, Fikret (TR) | 2024-12-18 | — | — | EP | disclosed |
| CN-119095622-A | NMDAR antagonists prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity | 菲克雷特·萨欣 | 2024-12-06 | — | — | CN | disclosed |
| WO-2023154014-A1 | NMDAR ANTAGONISTS PREVENT AGEING AND AGING-ASSOCIATED CONDITIONS AND DISEASES THROUGH INCREASING 20S PROTEASOME ACTIVITY | SAHIN FIKRET (TR) | 2023-08-17 | — | — | WO | disclosed |
| US-20170273917-A1 | NMDA RECEPTOR ANTAGONISTS FOR TREATING GAUCHER DISEASE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-09-28 | — | — | US | disclosed |
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | CHILDRENS MEDICAL CENTER (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-18 | — | — | US | disclosed |
| WO-2014160811-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| US-8058243-B2 | Method for treating a brain cancer with ifenprodil | HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP (CA) | 2011-11-15 | — | — | US | disclosed |
| US-5620979-A | TREATING NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA OR SURGERY | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| US-5597922-A | Glycine receptor antagonist pharmacophore | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1997-01-28 | — | — | US | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1996004288-A1 | GLYCINE RECEPTOR ANTAGONIST PHARMACOPHORE | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0557290-A1 | TREATMENT OF AIDS DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY, AND VISION LOSS | The Children's Medical Center Corporation (US) | 1993-09-01 | — | — | EP | disclosed |
| EP-0557290-A4 | TREATMENT OF AIDS DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY, AND VISION LOSS. | CHILDRENS MEDICAL CENTER (US) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992003137-A1 | TREATMENT OF AIDS DEMENTIA, MYELOPATHY, PERIPHERAL NEUROPATHY, AND VISION LOSS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1992-03-05 | — | — | WO | disclosed |
| JP-H0368519-A | GLUTAMIC ACID ANTAGONIST | SUMITOMO PHARMACEUT CO LTD | 1991-03-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058749-A1 | TREATMENTS FOR NEUROPATHY | NGF, BDNF, NTRK2 | KDM4E 4167/4885MEN1 3907/4885GRIN2D 982/4885 |
| US-20160045487-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY | PMP22, GAP43, NGF | KDM4E 2932/4885MEN1 3549/4885GRIN2D 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.